Alphamab Oncology IPO Initiation: Clear Diagnosis
Alphamab Co Ltd (1728643D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
484 Views
Hansoh Pharma's HS-10296 - How Far Is It From Billion $ Tagrisso? Our Read on Phase 2 Reports
Hansoh Pharma, a leading China-based pharmaceutical company, recorded a stellar post-IPO performance since its listing in June. As a big portion of...
468 Views
Immuno-Oncology Drugs in Adjuvant Lung: The Next Frontier in Strengthening Moats
The potential for Merck and Roche looks underappreciated.Innovation in immuno-oncology drugs has supported the moats for Merck & Co Inc. (MRK...
562 Views
U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom
In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting...
606 Views
Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views